Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1786 to 1800 of 2009 results for nice guidelines

  1. Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)

    Evidence-based recommendations on foslevodopa–foscarbidopa (Produodopa) for treating advanced Parkinson’s with motor symptoms in adults.

    Technology appraisal guidance
    Published
    29 November 2023
    View recommendations

    Sections for TA934

  2. In people with suspected TB, what is the relative clinical and cost effectiveness of universal andrisk-based use of rapid nucleic acid amplification tests?

    Any explanatory notes(if applicable) Why this is importantThe guideline committee noted that there were 2 possible approaches to using...

    Research recommendation
    Published
    8 November 2019

  3. What training, support or interventions help to reduce caring-related accidents or incidents?

    are included in the psychological and emotional support section of this guideline.By consensus, the committee also agreed to add some...

    Research recommendation
    Published
    10 February 2020

  4. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at moderately increased risk

    decision. It is based on the scientific evidence assessed by NICE when it produced its guideline on familial breast cancer....

  5. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at high risk

    decision. It is based on the scientific evidence assessed by NICE when it produced its guideline on familial breast cancer....

  6. Ustekinumab for treating moderate to severe plaque psoriasis (TA180)

    Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.

    Technology appraisal guidance
    Last updated
    3 March 2017
    View recommendations

    Sections for TA180

  7. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued Reference number: GID-TAG402

    Technology appraisal guidance
    Discontinued

  8. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

    Technology appraisal guidance
    Published
    22 September 2021
    View recommendations

    Sections for TA729

  9. Brodalumab for treating moderate to severe plaque psoriasis (TA511)

    Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    21 March 2018
    View recommendations

    Sections for TA511

  10. Patient and public involvement policy

    Read NICE's patient and public involvement policy.

  11. Patient and public involvement policy

    Read NICE's patient and public involvement policy.

  12. Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)

    Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.

    Technology appraisal guidance
    Published
    25 August 2021
    View recommendations

    Sections for TA722

  13. Obinutuzumab with mycophenolate mofetil for treating lupus nephritis (TA1131)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with mycophenolate mofetil for treating lupus nephritis in adults.

    Technology appraisal guidance
    Published
    12 February 2026

    Sections for TA1131

  14. Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)

    NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .

    Medtech innovation briefing
    Published
    30 July 2018

  15. PredictSURE IBD and IBDX to guide treatment of Crohn's disease (HTG610)

    Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease.

    HealthTech guidance
    Published
    23 February 2022
    View recommendations

    Sections for HTG610